| Literature DB >> 34970275 |
Cheng Wang1, Cheng Ma1, Lihong Gong1, Yuqin Guo1, Ke Fu1, Yafang Zhang1, Honglin Zhou1, Yunxia Li1.
Abstract
Macrophages are important immune cells in innate immunity, and have remarkable heterogeneity and polarization. Under pathological conditions, in addition to the resident macrophages, other macrophages are also recruited to the diseased tissues, and polarize to various phenotypes (mainly M1 and M2) under the stimulation of various factors in the microenvironment, thus playing different roles and functions. Liver diseases are hepatic pathological changes caused by a variety of pathogenic factors (viruses, alcohol, drugs, etc.), including acute liver injury, viral hepatitis, alcoholic liver disease, metabolic-associated fatty liver disease, liver fibrosis, and hepatocellular carcinoma. Recent studies have shown that macrophage polarization plays an important role in the initiation and development of liver diseases. However, because both macrophage polarization and the pathogenesis of liver diseases are complex, the role and mechanism of macrophage polarization in liver diseases need to be further clarified. Therefore, the origin of hepatic macrophages, and the phenotypes and mechanisms of macrophage polarization are reviewed first in this paper. It is found that macrophage polarization involves several molecular mechanisms, mainly including TLR4/NF-κB, JAK/STATs, TGF-β/Smads, PPARγ, Notch, and miRNA signaling pathways. In addition, this paper also expounds the role and mechanism of macrophage polarization in various liver diseases, which aims to provide references for further research of macrophage polarization in liver diseases, contributing to the therapeutic strategy of ameliorating liver diseases by modulating macrophage polarization.Entities:
Keywords: acute liver injury; alcoholic liver disease; hepatocellular carcinoma; liver disease; liver fibrosis; macrophage polarization; metabolic-associated fatty liver disease; viral hepatitis
Mesh:
Substances:
Year: 2021 PMID: 34970275 PMCID: PMC8712501 DOI: 10.3389/fimmu.2021.803037
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
The phenotypes, mechanisms and functions of macrophage polarization.
| Macrophage phenotypes | Stimulus | Specific markers | Cytokines | Mechanisms | Functions | References | |
|---|---|---|---|---|---|---|---|
| M1 | LPS, IFN-γ, GM-CSF | CD80, CD86, CD16/32, MHCII, iNOS | IL-1β, IL-6, IL-12, IL-23, TNF-α, CXCL1~3, CXCL8~10, CCL2~5, CCL11 | TLR4/NF-κB, IRF5, JAK/STAT1, Notch | Antigen presentation, Th1 immune reaction, proinflammation, pathogen elimination, anti-tumor | ( | |
| M2 | M2a | IL-4, IL-13 | CD206, MHCII, IL-1R, Dectin-1 | Arg1, IL-10, TGF-β, CCL17, CCL22 | JAK/STAT6, c-Myc, IRF4 | Anti-inflammation, wound healing, Th2 immune response, anaphylaxis, fibrosis | ( |
| M2b | LPS, IC | CD206, MHCII, CD86 | IL-10, IL-1β, IL-6, TNF-α, IL-12low | TLR4, Syk, PI3K | Immune regulation, pro-tumor, promoting infection | ( | |
| M2c | IL-10, TGF-β, glucocorticoid | CD206, CD163 | IL-10, TGF-β, Arg-1, CXCL13 | JAK/STAT3, NF-κB, TGF-β/Smads | Phagocytosis, immunosuppression, tissue remodeling | ( | |
| M2d | TLR agonist, A2AR ligand | CD206 | IL-10, VEGF, IL-12low, TNF-αlow | TLR4, NF-κB | Pro-tumor, angiogenesis | ( | |
| M4 | CXCL4 | MMP7+S100A8+, CD206, CD163-/- | TNF-α, CCL18 | N/A | Proinflammation, low phagocytosis | ( | |
| Mox | QxPAPC | HO-1, Srxn1, Gclc, Gclm | IL-1β, VEGF | Nrf2, Keap1, TLR2 | Low chemotaxis and phagocytosis | ( | |
| M(Hb) | Hemoglobin | CD206, CD163 | IL-10, IL-1R antagonist | PI3K/AKT, LXRα | Cholesterol loading resistance, ATP-binding cassette transporter up-regulation | ( | |
Figure 1The phenotypes and functions of macrophage polarization.
Figure 2The mechanisms of macrophage polarization.
The role and mechanisms of macrophage polarization in ALI.
| Regulation Factor | Research objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| Cannabinoid Receptor 2 | Mice, cells | M1→M2 | TLR4 signaling↓; miR-145↓ | 2015, America | ( |
| Protein interacting with C kinase 1 | Mice, cells | M1↓; M2↑ | NF-κB signaling↓; STAT6 signaling↑ | 2016, China | ( |
| P38α deficiency | Mice, cells | M1→M2 | CCL2, CCL5↓; p38α-CREB-C/EBPβ↓ | 2017, China | ( |
| Spermine | Mice, cells | M1↓; M2↑ | STAT1↓, STAT6↑; ATG5↑ | 2018, China | ( |
| Homeobox Containing 1 | Cells, mice | M1↓ | NF-κB signaling↓; MHCII↓ | 2018, China | ( |
| Benzenediamine Analog FC-99 | Mice, cells | M1↓; M2↑ | PPAR-γ signaling↑ | 2019, China | ( |
| p300/CBP inhibitor A-485 | Mice, cells | M1↓ | H3K27ac/H3K18ac↓; NF-κB, MAPK, NLRP3 signaling pathway↓ | 2019, China | ( |
| Human amniotic mesenchymal stromal cells | Mice, cells | M1↓; M2↑ | LC3B-II↑ | 2019, China | ( |
| Carbon monoxide | Mice, cells | M1↓; M2↑ | HIF-1α↓; PI3k/Akt/mTOR signaling↑ | 2021, China | ( |
| Msc-secreted prostaglandin E2 | Mice, cells | M2↑ | STAT6 and mTOR signaling↑ | 2021, China | ( |
|
| |||||
| Hyperglycemia | Mice, cells | M1↑; M2↓ | STAT1↑, STAT6↓; AMPK↓, PI3K/AKT pathway↑ | 2019, China | ( |
| CCL5 | Patient samples, mice | M2 ↓ | MAPK and NF-κB signaling pathway↑ | 2020, China | ( |
The role and mechanisms of macrophage polarization in viral hepatitis.
| Regulation Factor | Research objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| Scavenger receptor-AI | Mice, cells | M2↑ | MerTK↑, mTOR pathway↓ | 2017, America | ( |
|
| |||||
| Hepatitis B Core Antigen | Patient samples, cells | M2↓ | TLR2/NF-κB pathway↑; STAT6↓ | 2020, China | ( |
| HBV-miR-3 | Patient samples, cells | M1↑ | SOCS5↓; JAK/STA T signaling pathway↑ | 2020, China | ( |
|
| |||||
| HCV antigens | Patient samples, cells | M1↓ | A20/A20-binding inhibitor of NF-κB binding protein↑; NF-κB signaling↓ | 2015, China | ( |
| HCV core protein | Patient samples, cells | M1↓; M2↓ | TLR2 signaling↑; STAT1↓, STAT3↓ | 2016, China | ( |
| HCV single-stranded RNA | Patient samples, cells | M2↑ | TLR7/8 signaling↑ | 2017, America | ( |
| HCV E2 envelope glycoprotein | Cells | M2↑ | STAT1↓; STAT3↑ | 2019, America | ( |
The role and mechanisms of macrophage polarization in ALD.
| Regulation Factor | Research Objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| Cannabinoid CB2 receptor | Mice, cells | M1↓ | HO-1↑; NF-κB signaling↓ | 2011, France | ( |
| EV-miR-27a | Patient samples, cells | M2↑ | IL-10, TGF-β↑ | 2016, America | ( |
| β-caryophyllene | Mice | M1↓ | Cannabinoid 2 receptors↑; PPARα↑ | 2018, America | ( |
| β-hydroxybutyrate | Patient samples, mice, cells | M2↑ | Hcar2-cAMP pathway↑ | 2018, America | ( |
| Salidroside | Cells | M1↓ | Notch-Hes signaling pathway↓; NF-κB↓ | 2019, China | ( |
| Inulin | Mice, cells | M1↓; M2↑ | Short chain fatty acids↑; TLR4-MyD88-NF-κB pathway↓ | 2020, China | ( |
| Brain and Muscle Arnt-Like Protein-1 | Mice, cells | M1↓; M2↑ | S100A9 protein↑; glycolytic pathway↓ | 2021, China | ( |
| Metformin and Probiotics | Cells, rats | M1↓; M2↑ | MAPK/Nrf-2/HO-1 signaling pathway↑ | 2021, India | ( |
|
| |||||
| Telomerase reverse transcriptase | Mice, cells | M1↑ | NF-κB pathway↑ | 2016, China | ( |
| MiR-155 | Mice, cells | M1↑; M2↓ | PPARγ↓; C/EBPβ↓ | 2016, America | ( |
| Nogo-B | Patient samples, mice, cells | M1↑; M2↓ | C/EBP homologous protein↓; Endoplasmic reticulum stress↓ | 2017, America | ( |
| EV-Heat shock protein 90 | Mice, cells | M1↑; M2↓ | IκB kinase↑, TLR4/NF–κB pathway↑ | 2018, America | ( |
The role and mechanisms of macrophage polarization in MAFLD/NASH.
| Regulation Factor | Research Objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| β-Cryptoxanthin | Mice, cells | M1↓; M2↑ | JNK, p38 MAPK and NF-κB p65↓ | 2015, Japan | ( |
|
| Mice | M2↑ | TLR-4, NOX-4↓; MCP-1, PPAR-γ↓ | 2015, Korea | ( |
| Astaxanthin | Patient samples, mice, cells | M1↓; M2↑ | p38 MAPK↓, NF-κB↓, JNK↓ | 2015, Japan | ( |
|
| Mice | M2↑ | PPAR-α↑; PPAR-γ↓; TLR4/NF-κB pathway↓ | 2016, South Korea | ( |
| Glucoraphanin | Mice, cells | M1↓; M2↑ | Nrf2 ↑; JNK↓; ERK↓; NF-κB p65↓ | 2017, Japan | ( |
| Honokiol | Mice | M2↑ | PPAR-γ signaling↑ | 2018, China | ( |
| Retinoic-acid-related orphan receptor α | Mice, cells | M2↑ | Kruppel-like factor 4↑ | 2017, Korea | ( |
| Saxagliptin | Rats, cells | M1↓; M2↑ | CaMKKβ/AMPK pathway↑; NF-κB↓ | 2018, China | ( |
| Mucosal-associated invariant T cells | Patient samples, mice, cells | M2↑ | MHCI-related molecule↑; IL-4↑ | 2018, China | ( |
| IL-25 | Mice, cells | M2a↑ | IL-13/STAT6 pathway↑ | 2019, China | ( |
| Raptor | Patient samples, mice, cells | M2↑ | Dynamin-related protein 1↑ | 2019, China | ( |
|
| Mice | M1↓ | IL-1β, TNF-α↓; miR-122-5p, miR-192-5p↓ | 2019, America | ( |
| Liraglutide | Mice, cells | M2↑ | cAMP-PKA-STAT3 signaling pathway↑ | 2019, China | ( |
| Fermented Korean red ginseng | Mice, cells | M2↑ | mTOR complex 1 signaling↓ | 2019, Korea | ( |
| Rosiglitazone | Cells, mice | M1→M2 | PPARγ↑; TLR4/NF-κB signaling pathway↓ | 2020, China | ( |
| Myricetin | Mice, cells | M1↓; M2↑ | TREM-1-TLR2/4-MyD88 signaling↓; NF-κB↓; p-STAT3↓ | 2020, China | ( |
| Eccentric exercise and Caloric restriction | Mice | M1↓; M2↑ | MCP1, TNF-α, IL-1β, IL-6↓; IL-10↑ | 2020, China | ( |
| Anagliptin | Mice, cells | M1↓; M2↑ | Dipeptidyl peptidase-4↓; NF-κB p65, p38 MAPK, ERK, JNK↓ | 2020, Japan | ( |
| Annexin A5 | Mice, cells | M1→M2 | Pyruvate kinase M2↓ | 2020, China | ( |
| Amlexanox | Cells | M2↑ | TBK1/IKKϵ-NF-κB signaling pathway↓; IRF3 pathway↓ | 2020, Korea | ( |
| Metformin and Genistein/Chlorogenic | Mice | M2↑ | NF-κB↓; p-AMPK↑ | 2020, Iran | ( |
| Dasatinib | Mice | M2↑ | COX2, SREBP-1, p-PDGFR↓; NF-κB↓ | 2021, Egypt | ( |
| CD4 derived double negative T cells | Mice, cells | M1↓ | TLR4, CCR2, TNF-α↓ | 2021, China | ( |
| G protein-coupled bile acid receptor 1 | Patient samples, mice, cells | M1↓ | NLRP3 inflammasome activation↓ | 2020, China | ( |
|
| |||||
| Histone methyltransferase Suv39h2 | Patient samples, mice, cells | M1↑ | Sirt1↓; NF-κB↑; PPAR-γ↓ | 2017, China | ( |
| CD44 | Patient samples, mice | M1↑; M2↓ | MCP-1/CCL2/CCR2↑ | 2017, France | ( |
| MiR-141/200C | Patient samples, mice, cells | M1↑; M2↓ | P-AMPK/AKT/GSK3↓; TLR4, p-mTOR/4EBP1↑ | 2017, America | ( |
| P62-positive inclusion body | Patient samples | M1↑ | Nrf2↑ | 2018, Japan | ( |
| HSPA12A | Patient samples, mice, cells | M1↑ | Nuclear M2 isoform of pyruvate kinase↑ | 2019, China | ( |
| Iron overload | Mice, cells | M1↑; M2↓ | KLF4↓, STAT6↓ | 2019, America | ( |
| P38α | Patient samples, mice | M1↑ | TLR4↑; TNF-α, CXCL10, IL-6↑ | 2019, China | ( |
| Cholesterol | Patient samples, cells | M1↑ | Exosomal miR-122-5p↑ | 2020, China | ( |
| Hepatocyte-derived exosomal miR-192-5p | Patient samples, rats | M1↑ | Rictor↓; p-Akt/p-FoxO1↓; FoxO1↑ | 2020, China | ( |
|
| Patient samples, mice, cells | M1↑ | TLR2/NLRP3 pathway↑; mTOR-S6K1-SREBP-1/PPAR-α signaling↑ | 2020, China | ( |
The role and mechanisms of macrophage polarization in LF.
| Regulation Factor | Research Objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| γ-secretase inhibitor | Patient samples, cells, CCl4-treated mice | M1↓ | Notch signaling↓ | 2015, Netherlands | ( |
| Cells, schistosome-infected mice | M2↓ | 2016, China | ( | ||
| NKp46+ cells | MCD-fed mice, cells | M1↑ | IFN-γ↑ | 2016, America | ( |
|
| Cells, schistosome-infected mice | M1↑ | NF-κB↑; p-p38 MAPK↓; MMP-13↑; TGF-β1↓ | 2018, China | ( |
| Lentiviral GRA15II | 2018, China | ( | |||
| Corilagin | Schistosome-infected mice | M2↓ | SOCS1, KLF, PPARγ, PPARδ↓; IL-13/STAT6 signaling pathway↓ | 2016, China | ( |
| Phosphatase and tensin homolog deleted on chromosome 10 | CCl4-treated mice, cells | M2↑ | PI3K/Akt/STA T6 signaling↑ | 2017, China | ( |
| S-allyl-glutathione | CCl4-treated rats, cells | M1↓; M2↓ | heat shock protein 47↓ | 2018, Japan | ( |
| DMN-treated rats, cells | M2↓ | ||||
| Quercetin | CCl4-treated mice, cells | M1↓ | Notch1 pathway↓ | 2018, China | ( |
| Proline–serine–threonine–phosphatase-interacting protein2 | CCl4-treated mice, cells | M1↓; M2↑ | STAT1↓; STAT6↑ | 2018, China | ( |
| Bone marrow MSC transplantation | CCl4-treated mice, cells | M1↓; M2↑ | MMP13↑; IL-10↑, ΤGF-β1↓; caspase-3↑ | 2019, China | ( |
| Splenectomy | ConA-treated mice | M2↑ | NF-κB p65/p50↓ | 2019, China | ( |
| Recombinant Sj16 protein | Schistosome-infected mice, cells | M2↑ | Arg-1, IL-10↑; Th1 response↓ | 2019, China | ( |
| Margatoxin | CCl4-treated mice, cells | M1↓; M2↑ | P-STAT1↓; p-STAT6↑ | 2020, China | ( |
| TNF-stimulated gene 6 | CCl4-treated mice | M2↑ | P-STAT1/3, p-p65, p-Akt↓; NF-κB↓ | 2020, China | ( |
| Endoplasmic reticulum stress | CCl4-treated rats, cells | M1↑ | TNF-α↑; TNF-R1/caspase 8↑ | 2020, China | ( |
| Capsaicin | CCl4-treated rats, cells | M1↓ | Notch signaling↓; TNF-α↓ | 2020, China | ( |
| IL-22 | CCl4-treated mice, cells | M1→M2 | Erk1/2 and Akt pathways↓; STAT3 pathway↑ | 2021, China | ( |
|
| |||||
| Cytochrome P450 2E1 | Patient samples, DEN-treated mice | M2↓ | CD163/CD68 ratio↓ | 2019, China | ( |
| PC3-secreted microprotein | Patient samples, CCl4-treated mice | M1↑ | CCR2↑ | 2020, China | ( |
| LncRNA Lfar1 | Cells, CCl4 and BDL-treated mice | M1↑ | NLRP3 inflammasome↑; NF-ĸB pathway↑ | 2020, China | ( |
| Activated HSCs | Patient samples, cells | M2↑ | CCL2/CCR2 pathway↑ | 2021, China | ( |
The role and mechanisms of macrophage polarization in HCC.
| Regulation Factor | Research Objects | Macrophage polarization | Mechanisms | Year and Country | Reference |
|---|---|---|---|---|---|
|
| |||||
| Cantharidin | Cells, mice | M2→M1 | STAT3↓; miR-214↑; β-catenin↓ | 2014, China | ( |
| Baicalin | Cells, mice | M2→M1 | RelB/p52 pathway↑ | 2015, China | ( |
| GdCl3 | Patient samples, mice, cells | M2↓ | E-cadherin↑; N-cadherin, TWIST, Snail↓; CD206↓ | 2015, China | ( |
| IL-12 | Cells, mice | M1↑ | STAT3/C-Myc pathway↓ | 2016, China | ( |
| ToxoGRA15II | Cells, mice | M1↑ | MMP-9, MMP-2↓; IL-6, IL-10↓; TNF-α, IL-12↑ | 2017, China | ( |
| LncRNA cox-2 | Cells, mice | M1↑; M2↓ | p50/p65↑; COX-2↑ | 2018, China | ( |
| MiR-98 | Cells | M2→M1 | TNF-α, IL-1β↑; TGF-β, IL-10↓; EMT↓ | 2018, China | ( |
| SPON2 | Patient samples, mice, cells | M1↑ | Integrin-Rho GTPase-Hippo pathways↑ | 2018, China | ( |
| Cryptotanshinone | Cells, mice | M1↑ | TLR7/MyD88/NF-κB signaling pathway↑ | 2019, America | ( |
| Sirtuin 1 | Patient samples, cells | M1↑ | NF-κB pathway↑ | 2019, China | ( |
| Sirtuin 4 | Patient samples, cells, mice | M2↓ | FAO-PPARδ-STAT3 signaling pathway↓ | 2019, China | ( |
| IL-37 | Patient samples, cells, mice | M2→M1 | IL-6/STAT3 pathway↓ | 2020, China | ( |
| Retinoic acid-inducible gene I | Patient samples, cells, mice | M1↑ | MAVS/TRAF2/NF-κB pathway↑ | 2020, China | ( |
| 4−methylumbelliferone | Mice, cells | M1↑ | IL-6↓; TLR4, CD47, Sox2↓ | 2021, Australia | ( |
|
| Cells, mice | M1↑ | TNF-α, IL-1β, IL-6, TGF-β1↑; PI3K/AKT pathway↑ | 2021, China | ( |
| MiR-144/451a cluster | Patient samples, mice, cells | M1↑ | hepatocyte growth factor (HGF)↓; migration inhibitory factor (MIF)↓ | 2021, China | ( |
|
| |||||
| Oxidored-nitro domain-containing protein 1 | Patient samples, mice, cells | M2↑ | Arg1, IL-10↑; IL-6, NF-κB↑ | 2018, China | ( |
| N-myc downstream-regulated gene 2 | Cells, mice | M1↓ | NF-κB signaling pathway↓ | 2018, China | ( |
| Wnt ligands | Patient samples, mice, cells | M2↑ | Wnt/β-catenin signaling↑ | 2018, China | ( |
| Neurotensin | Patient samples, cells, mice | M2↑ | IL-8↑; MAPK and NF-κB pathways↑ | 2018, China | ( |
| Sal-like protein-4 | Patient samples, cells, mice | M2↑ | Exosomal miR-146a-5p↑ | 2019, China | ( |
| Intestinal dysbacteriosis | Patient samples, cells, mice | M2↑ | IL-25↑; CXCL10↑ | 2019, China | ( |
| LncRNA LINC00662 | Patient samples, cells, mice | M2↑ | Wnt/β-catenin signaling↑ | 2020, China | ( |
| LncRNA MALAT1 | Patient samples, cells, mice | M2↑ | MiR-140↓; VEGF-A↑ | 2020, China | ( |
| Extracellular ubiquitin | Patient samples, cells, mice | M2↑ | CXCR4/ERK signaling pathway↑ | 2020, China | ( |
| LncRNA TP73-AS1 | Patient samples, cells, mice | M2↑ | MiR-539↓; MMP8↑; TGF-β signaling↑ | 2020, China | ( |
| Nogo-B | Patient samples, cells, mice | M2↑ | Yes-associated protein (Yap)/transcriptional coactivator with PDZ-binding motif (Taz)↑ | 2020, China | ( |
| High−mobility group box 1 | Cells, mice | M2↑ | TLR2/NOX2/autophagy axis↑ | 2020, China | ( |
| Arsenite | Cells, mice | M2↑ | MiR-15b↑; large tumor suppressor kinase 1↓; Hippo pathway↓ | 2021, China | ( |
| lncRNA-CRNDE | Cells, mice | M2↑ | JAK1/STAT6, AKT1↑; Notch1↑ | 2021, China | ( |
| Cancer−associated fibroblast | Cells | M2↑ | CXCL12↑; plasminogen activator inhibitor−1↑ | 2021, Japan | ( |
| Cyclooxygenase-2 | Patient samples, mice, cells | M2↑ | TGF-β-Smad2/3↑; FoxP1↑ | 2021, China | ( |
| Epithelial cell transforming 2 | Patient samples, cells, mice | M2↑ | PLK1/PTEN pathway↑ | 2021, China | ( |
| Distal-less homeobox 6 antisense 1 | Patient samples, cells, mice | M2↑ | MicroRNA-15a-5p↓; CXCL17↑ | 2021, China | ( |
Figure 3The ameliorative effects of macrophage polarization on various liver diseases.